key articles
PSA velocity predicts high-risk prostate cancer
Tuesday, 11 November 2008 - The identification of high-risk prostate cancer in men is improved by measuring prostate-specific antigen (PSA) velocity, but not PSA doubling time, US researchers have discovered.
PSA velocity is...
Edited by: JV
Current criteria for active surveillance in low-risk prostate cancer patients
Monday, 10 November 2008 - Active surveillance (AS) represents a treatment option for select patients with low-risk, organ-confined prostate cancer (PCa). Suardi et al. (2008) addressed the rates of misclassification associated...
Authors: Suardi et al.
Cholesterol-lowering drugs may lower PSA but impact on cancer risk remains unknown
Thursday, 6 November 2008 - Popular cholesterol-busting drugs such as statins appear to lower men's PSA values along with their cholesterol levels, but whether the drugs prevent prostate cancer growth remains unknown, according...
Edited by: JV
Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer
Saturday, 1 November 2008 - Atrasentan is a potent, oral, selective endothelin-A (ETA) receptor antagonist that has clinical activity in patients with hormone-refractory prostate cancer (HRPC). Nelson et al. (2008) reported the...
Authors: Nelson et al.
High PSA also predicts aggressive recurrence following radical prostatectomy
Friday, 31 October 2008 - The factors that are invariably used to predict overall biochemical recurrence following radical prostatectomy, including high prostate specific antigen, high grade and adverse pathological findings,...
Edited by: FGR
Prospective evaluation of sexual function in patients receiving cryosurgery as a primary radical treatment for localized prostate cancer
Thursday, 30 October 2008 - The development of 17 G cryotherapy probes has improved the outcome of this treatment, but one of the side-effects of cryosurgery is the development of erectile dysfunction (ED). Asterling and Greene...
Authos: Asterling & Greene
Role of radical treatment in the management of low-risk prostate cancer
Wednesday, 29 October 2008 - A number of forms of radiation therapy are now commonly used for the treatment of low-risk prostate cancer (LRPCa). The tumour control rates are typically excellent, and the risk of death from...
Authors: Williams & Zietman
Long-term assessment of prostate cancer progression free survival
Tuesday, 28 October 2008 - Molecular pathways of proliferation, angiogenesis, neuroendocrine differentiation, apoptosis and alterations in nuclear structure of cancer epithelial cells are important in the pathogenesis of prostate...
Authors: Veltri et al.
Computerized whole slide quantification shows increased microvascular density in pT2 prostate cancer as compared to normal prostate tissue
Tuesday, 28 October 2008 - Contrast enhanced imaging enables powerful, non-invasive diagnostics, important for detection and staging of early prostate cancer. The uptake of contrast agent is increased in prostate cancer as...
Authors: van Niekerk et al.
New immunotherapy shows promising activity against hormone naive prostate cancer
Tuesday, October 28, 2008 - Granulocyte-macrophage colony-stimulating factor secreting cellular immunotherapy has a favorable toxicity profile with signals of clinical and immunological activity against hormone naïve prostate...
Edited by: FGR
